Spiliopoulos Sotirios, Hergesell Vera, Wasler Andrae, Dapunt Otto
Medical University of Graz, Department of Cardiac Surgery, Graz, Austria.
Biomed Tech (Berl). 2019 May 27;64(3):247-250. doi: 10.1515/bmt-2017-0095.
Due to the declining instances of organ donation, total artificial heart (TAH) therapy is of increasing importance for the management of end-stage biventricular heart failure. We introduce the currently most important established and novel TAH systems (SynCardia, CARMAT, ReinHeart, BiVACOR), report clinical outcomes and discuss technical requirements for the successful implementation of TAH therapy as an alternative to cardiac transplantation.
由于器官捐献案例的减少，全人工心脏（TAH）疗法对于终末期双心室心力衰竭的治疗愈发重要。我们介绍了当前最重要的已确立和新型TAH系统（SynCardia、CARMAT、ReinHeart、BiVACOR），报告了临床结果，并讨论了成功实施TAH疗法作为心脏移植替代方案的技术要求。
